for the selection of the most appropriate thera peutic strategy. In comparison with conventional methods, such as US, CT, BS and mammography, PET/CT has been shown to have superior specific ity and sensitivity in the detection of distant me tastases [2] . False negative PET/CT results can occur because of low FDG uptake in some condi tions, such as invasive lobular carcinoma, less well visualized lesions in the visceral cavity and poor imaging of the limbs and brain. False positive re sults, on the other hand, may occur in inflamma tions. In a metaanalysis by Pennant et al. [3] , PET/ /CT had significantly higher accuracy as compared with CT or PET alone for the diagnosis of recur rent breast cancer. No significant differences were found in the sensitivity or specificity of PET (with or without CT) when compared with MRI [3] [4] . Since PET/CT and MRI have shown considerable effective in the verification of breast cancer recur rence or metastases, PET/MRI may become a pow erful and promising technique in clinical oncology in the near future.
Schmidt et al. found PET/CT to be more sen sitive than whole bodyMRI (WBMRI) in de tecting lymph node involvement [4] . In addition, PETCT detected more osteolytictype bone le sions than osteoblastic lesions as compared with BS [5] . One possible reason for this difference may be that osteoblast proliferation in osteosclerotic le sions increases the bone matrix, where FDG up take is lower. Osteoblastic metastases usually do not show increased glucose intake and are better detected with BS.
Evangelista et al. carried out a systematic re view involving 13 studies from 2001 to May 2011, which showed that fluorodeoxyglucose PET, and in particular PET/CT, allows 83% accuracy in the assessment of the site and extent of the recurring disease when the clinician is confronted with sus picious elevated serum tumor markers in asymp tomatic breast cancer patients following prima ry treatment and negative conventional imaging findings [6] .
In breast cancer patients suspected of disease recurrence, CA153 levels, as well as increases in CA153 levels over time, have proven systemati cally higher in PETpositive patients when com pared with PETnegative patients. However, no single cutoff value yielding an acceptable sensi tivity and specificity has been identified for either variable. Rather, it is the combination of increas es in CA153 over time along with a clinical suspi cion of disease progression that should prompt the clinician to perform PET/CT imaging. The limited data available further suggests that this approach will likely affect treatment management in up to 50% of patients [7] . Evangelista et al. retrospectively studied 60 breast cancer patients who had already undergone systemic therapy for primary disease. Three seri al measures of Ca153 were collected individual ly within one year before PET/CT examination: at 12-9 months, at 9-3 months, and at 3-0 months. The study showed that an increase in Ca153 at 9-3 months and 3-0 months correlates with accurate positive PET/CT results and disease re lapse (p < 0.05).During a breast cancer patient's followup, serial elevated Ca153 could be a hint to the clinician to perform a PET/CT examination to detect disease relapse when the disease is more treatable [8] .
These findings indicate that PET/CT is an accurate, sensitive and reliable modality for the screening and detection of breast cancer recur rence. According to the 2014 National Compre hensive Cancer Network guidelines (NCCN 2014 v. 3) FDG PET/CT is highly recommended for the detection of suspicious or equivocal metastatic le sions and bone metastasis [9] .
FDGPET/CT appears to be an effective sur veillance tool; the technique is able to assess the whole body in a single procedure and performs well. More prospective studies are needed to de termine whether this technology could potentially replace conventional imaging tests used today to monitor breast cancer recurrence.
Assessment of Response to Therapy
Neoadjuvant chemotherapy (NAC) has long been a standard therapy for stage II and III breast cancer [10] . It is generally accepted that an ab sence of residual cancer cells in the primary tu mor following NAC is strongly associated with improved diseasefree survival and overall surviv al [11] . However, in most NAC studies less than 30% of patients achieve complete response [12] . Thus, find an effective way to predict response ear ly during NAC is important so that physicians can change strategies in case of ineffectiveness, thereby avoiding unnecessary side effects to patients.
A correlation has been demonstrated between early changes in the maximum standardized up take value (after one or two courses of chemother apy) and the final treatment response at the com pletion of NAC [13] [14] [15] . Relative changes in both the maximum standardized uptake value (SUV max) and standardized uptake value (SUV) have been proposed as a means to discriminate meta bolic responders from nonresponders or to differ entiate between pathological complete response (pCR) and nonpCR [13] [14] [15] . Recently, a study by Andrade et al. demonstrated that the optimal per centage change in posttreatment SUV scores rel ative to baseline (ΔSUV) to discriminates between pCR and nonpCR was -71.8% (83.3% sensitivi ty; 78.5% specificity); the optimal ΔSUV thresh old to discriminate between NAC responders and nonresponders was -59.1% (68% sensitivity; 75.0% specificity) [16] . Unfortunately, the optimal threshold value varies dramatically across studies.
There are still studies suggesting that other im aging tests, such as MRI, when combined with tu mor diameter detection, are better than the change in SUV for evaluating response to NAC [17] . How ever, in general more and more data support the role of FDG PET/CT in the early evaluation of re sponse to NAC. Better defined criteria for PET/CT evaluation are needed. MRI is also useful in the early evaluation of response to NAC, and the place of PET/CT in comparison with MRI needs to be better determined [18] .
It is possible that PET/CT can detect tumor response metabolically earlier than morphologic imaging methods in order to evaluate treatment response in metastatic breast cancer. First, for tar geted therapies, tumors always change metabo lically earlier than their size changes. Second, for endocrine therapy, several studies have shown that an increase in tumor FDG uptake 7-10 days after initiating endocrine therapy is predictive of a good response [19] [20] . This phenomenon can be ex plained by the fact that endocrine therapy has ini tial agonist effects before antagonist effects domi nate. Therefore, an increase in SUV in tumors soon after the initiation of hormone therapy is predic tive of a good therapeutic response. One study by MortazaviJehanno et al. found that "metabolic re sponse assessed by FDG PET/CT imaging in meta static breast cancer treated with endocrine therapy is predictive of the patients' (progressionfree sur vival)" [21] . However, data are lacking on the de layed effect of endocrine therapy on tumor meta bolism. Third, PET/CT is also helpful in providing evidence of a heterogeneous response (that is, the coexistence of responding and nonresponding lesions within the same patient) [22] .
Newer evaluation criteria are needed that take into account not only the PET but also the CT of hybrid imaging. Although there are few stud ies evaluating PET/CT in metastatic breast cancer treatment, this modality does have some advan tages over other imaging. More data are needed, and standardization in the criteria for evaluation is necessary.
Previous research has evaluated correlations between the difference in SUV in dual timepoint imaging and biological prognostic factors [23] [24] [25] . Little is known, however, as to whether the meta bolic characteristics of breast cancer differ in rela tion to molecular subtypes. Triplenegative breast tumors (negative for estrogen and progesterone receptors, and no HER2/neu overexpression) are currently the subject of major interest because of the aggressiveness of these tumors, their poor prognosis and the lack of targeted therapy. Some studies focusing on triplenegative breast cancer (TNBC) have shown that the SUV of the primary lesion in the TNBC group was significantly high er than in nonTNBC [23, 26] . One study by Ke am et al. showed that the estrogen receptornega tive phenotype had a higher percentage change in SUV and prechemotherapy SUV than other phenotypes [26] . NonTNBC has lower preche motherapy SUV than TNBC patients (9.8 vs. 6.4, p = 0.008) [25] . Early metabolic nonresponse was always associated with pathologic nonresponse and a poor prognosis in ERpositive/HER2nega tive patients. In this subtype, PET/CT might be use ful to select patients who will probably benefit from early therapeutic strategy modifications [27, 28] .
Recently, Koolen et al. evaluated the effect of 18FFDG PET/CT in monitoring responses to NAC in 98 breast cancer patients. They found that the accuracy of response monitoring with PET/ /CT was much higher in the ERpositive/HER2 negative and triplenegative subtypes than in the HER2positive subtype. They speculated that this phenomenon could be explained by an initial in flammatory response induced by trastuzumab treatment in HER2positive subtype patients [29] .
There are other oncologic PETtracers for the management of breast cancer. PET with 18FFLT enables investigators to quantify the proliferation fraction of tumors [30] and has been proposed as a better biomarker than FDGPET for measuring response to therapy [31] . In a study of 14 breast cancer patients, FDGPET and FLTPET were per formed at baseline, two weeks after the first cycle of chemotherapy or endocrine therapy and after the completion of treatment [32] . Early changes in FLT uptake showed a stronger correlation with clinical outcome than did FDG. According to preliminary results from a pilot study, changes in the number of circulatory tumor cells (CTCs) seem to be corre lated with changes in FLTPET uptake in metasta tic lesions during the course of therapy [33] . Larger prospective trials are needed to define the potential role of FLTPET for treatment monitoring.
Another biomarker, 16a18Ffluoro17bes tradiol (FES), is a steroidbased positron emission tomography tracer that has been shown to be a re liable tracer for the management of ERpositive breast cancer patients. Low FES uptake in tumor lesions shows a strong predictive value for failure of antihormonal therapy [34] . Yet another bio marker, 21[F18]fluoro16a,17a[(R)(19afuryl methylidene)dioxy]19norpregn4ene3,20dione (FFNP), shows a high affinity and selectivity for progesterone receptors (PR) [35] . In the future, FFNPPET may allow for the noninvasive detec tion and quantification of PRpositive lesions.
[Zr89]trastuzumab, which shows an excel lent uptake in HER2positive lesions in liver, lung, bone and brain metastases, may allow for a whole body assessment of the HER2 receptor status in metastatic/recurrent breast cancer. However, so far few reports have described the use of this bio marker in breast cancer patients [36] .
Piccardo et al. found that (18) FFluoride PET/multidetector row spiral CT (MDCT) with 1.25 mm section thickness image reconstruction has a higher diagnostic accuracy for bone metasta ses than does PET/CT and MDCT [37] .
It has also recently been argued that 18 Fso dium fluoride (18FNaF) PET/CT might prove a useful alternative to detect bone reaction to meta static involvement. Combined NaF/FDGPET/CT has shown promising early results using the same amount of radiation as BS and FDGPET/CT [38] . According to Gradishar et al., if a FDG PET/CT scan clearly indicates bone metastasis on both the PET and CT components, a bone scan or sodium fluoide PET/CT may not be needed [9] . In some conditions, considering the coexistence of both lytic and sclerotic lesions and the different mecha nisms of radiotracer uptake, PET and BS are mu tually complementary methods for the diagnosis of bone metastasis [38] .
Conclusions
Studies to date support the following conclu sions: 1) PET/CT can be used earlier than morpho logic imaging methods to evaluate the response to chemotherapy, targeted therapy and endocrine treatment in breast cancer. 2) Serial elevated Ca153 could be a hint to the clinician to perform a PET/CT examination to detect disease relapse when the dis ease is at a more treatable stage. 3) TNBC was sig nificantly associated with a higher SUV (max) and relatively good response to NAC. 4) New PET bio markers, including those that detect the rate of cell proliferation and the expression of estrogen recep tors, seek to improve patients' restaging informa tion and the evaluation of therapeutic effective ness. Further studies are needed to evaluate these new imaging strategies and their clinical utility. It is likely that in the future those patients who are unlikely to benefit from chemotherapy could be identified by a pretreatment PET/CT test.
